Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Puma, but not noxa is essential for oligodendroglial cell death.
Circulating monocytes are reduced by sphingosine-1-phosphate receptor modulators independently of S1P3.
Overcoming barriers in progressive multiple sclerosis research.
Ozanimod (RPC1063) is a potent sphingosine-1-phosphate receptor-1 (S1P1R ) and receptor-5 (S1P5R ) agonist with autoimmune disease-modifying activity.
Rescue Therapy Using Rituximab for Multiple Sclerosis.
A complex role of herpes viruses in the disease process of multiple sclerosis.
Effect of peginterferon beta-1a on MRI measures and achieving no evidence of disease activity: results from a randomized controlled trial in relapsing-remitting multiple sclerosis.
Cognitive impairment and cortical degeneration in neuromyelitis optica.
Gait variability measures reveal differences between multiple sclerosis patients and healthy controls.
Gene expression analysis of relapsing-remitting, primary progressive and secondary progressive multiple sclerosis.
Dalfampridine sustained-release for symptomatic improvement of walking speed in patients with multiple sclerosis.
FTY720 in patients with primary progressive multiple sclerosis (INFORMS)
Multiple associations between a broad spectrum of autoimmune diseases, chronic inflammatory diseases and cancer.
Normal-appearing white matter in multiple sclerosis is in a subtle balance between inflammation and neuroprotection.
Activation of axonal Kv7 channels in human peripheral nerve by flupirtine but not placebo - therapeutic potential for peripheral neuropathies: results of a randomised controlled trial.
White matter astrocytes in health and disease.
Safety issue puts daclizumab in doubt for MS
Does interferon Beta-1a impact pure-tone hearing sensitivity among individuals with multiple sclerosis?
Reactive astrocytes form scar-like perivascular barriers to leukocytes during adaptive immune inflammation of the CNS.
A high-density screen for linkage in multiple sclerosis.
Synthesis and biological evaluation of new 1,2-dihydro-4-hydroxy-2-oxo-3-quinolinecarboxamides for treatment of autoimmune disorders: structure-activity relationship.
Sanofi withdraws Campath in US and EU
Modeling probability of additional cases of natalizumab-associated JCV sero-negative progressive multifocal leukoencephalopathy.
Glatiramer acetate does not protect from acute ischemic stroke in mice.
The Stigma Scale for Chronic Illnesses 8-Item Version (SSCI-8): Development, Validation and Use Across Neurological Conditions.

Pages